Advertisement
UK markets close in 2 hours 8 minutes
  • FTSE 100

    8,117.92
    +39.06 (+0.48%)
     
  • FTSE 250

    19,788.45
    +186.47 (+0.95%)
     
  • AIM

    754.65
    +1.53 (+0.20%)
     
  • GBP/EUR

    1.1664
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2502
    -0.0009 (-0.07%)
     
  • Bitcoin GBP

    51,023.32
    +803.13 (+1.60%)
     
  • CMC Crypto 200

    1,385.44
    -11.09 (-0.79%)
     
  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     
  • DOW

    38,085.80
    -375.12 (-0.98%)
     
  • CRUDE OIL

    84.29
    +0.72 (+0.86%)
     
  • GOLD FUTURES

    2,360.40
    +17.90 (+0.76%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,078.11
    +160.83 (+0.90%)
     
  • CAC 40

    8,057.06
    +40.41 (+0.50%)
     

How Novartis’s Cosentyx Is Positioned after 3Q17

In 3Q17, Novartis’s Cosentyx generated revenues of $556 million, which reflected a whopping 85% growth YoY (year-over-year) and ~13% growth QoQ.